NMN/NR and Finasteride: Interaction Risk, Shared Pathways, and Clinical Guidance

Why This Combination Is Increasingly Common

Men prescribed finasteride 1 mg for androgenetic alopecia or 5 mg for benign prostatic hyperplasia (BPH) are increasingly adding NAD+ precursors to their supplement regimen. NMN and NR have gained popularity after preclinical studies demonstrated age-related NAD+ decline and potential benefits from repletion.

Finasteride remains one of only two FDA-approved oral treatments for male pattern hair loss, with the agency first approving the 1 mg dose (Propecia) in 1997 [1]. Separately, NMN entered human clinical trials in the early 2020s, with Yoshino et al. (2021, N=25) reporting improved muscle insulin sensitivity in prediabetic women receiving 250 mg/day for 10 weeks [2]. NR has a slightly longer clinical track record. Martens et al. (2018, N=30) showed that 1,000 mg/day of NR for 6 weeks was well-tolerated in healthy adults aged 55 to 79, raising whole-blood NAD+ by approximately 60% without serious adverse events [3].

The clinical question is straightforward: do these compounds interfere with each other? The short answer is no, based on available pharmacokinetic and pharmacodynamic data. But the longer answer requires examining each metabolic pathway in detail.

Finasteride Pharmacokinetics: The CYP3A4 Story

Finasteride is absorbed rapidly after oral administration, reaching peak plasma concentration in 1 to 2 hours. Bioavailability is roughly 80%, and the drug is approximately 90% protein-bound in plasma [1].

The liver handles virtually all of finasteride's biotransformation. According to the FDA-approved prescribing information, finasteride is metabolized primarily by the cytochrome P450 3A4 enzyme (CYP3A4), with a minor contribution from CYP3A5 [1]. The two major metabolites, the t-butyl side chain monohydroxylated and monocarboxylic acid forms, retain less than 20% of the 5-alpha reductase inhibitory activity of the parent compound [4]. Terminal half-life ranges from 5 to 6 hours in men aged 18 to 60, extending to roughly 8 hours in men over 70.

The drug is not a significant inhibitor or inducer of CYP3A4 at therapeutic doses. It does not meaningfully alter P-glycoprotein (P-gp) transporter function. These characteristics narrow the window for pharmacokinetic interactions substantially.

NMN and NR Metabolism: A Non-CYP Pathway

NMN and NR follow an entirely different metabolic route than conventional pharmaceuticals. Neither compound relies on cytochrome P450 enzymes for activation or clearance.

NMN is converted to NAD+ in two steps. First, NMN enters cells via the Slc12a8 transporter (identified in murine models) or is dephosphorylated to NR extracellularly, then re-phosphorylated intracellularly [5]. The nicotinamide riboside kinases NRK1 and NRK2 phosphorylate NR back to NMN, and nicotinamide mononucleotide adenylyltransferases (NMNAT1, NMNAT2, NMNAT3) catalyze the final conversion of NMN to NAD+ [6]. NR follows the same downstream pathway beginning at the NRK step.

No published evidence indicates that NMN or NR inhibits, induces, or serves as a substrate for CYP3A4, CYP2D6, CYP2C9, CYP1A2, or any other major cytochrome P450 isoform [6]. The compounds also have no documented interaction with P-gp, OATP1B1, or other clinically relevant drug transporters.

This mechanistic separation is the primary reason the combination carries low pharmacokinetic risk. Finasteride's CYP3A4-dependent clearance and NMN/NR's kinase-dependent activation operate on parallel, non-overlapping enzymatic tracks.

Pharmacodynamic Considerations: NAD+ and the Androgen Axis

While the pharmacokinetic picture is reassuring, the pharmacodynamic relationship deserves closer examination. Both NAD+ metabolism and 5-alpha reductase activity intersect with androgen signaling at the cellular level, though through different mechanisms.

Finasteride competitively inhibits type II 5-alpha reductase, blocking the conversion of testosterone to dihydrotestosterone (DHT). In men taking 1 mg daily, serum DHT decreases by approximately 70%, while testosterone levels may rise modestly by 10% to 15% [1]. This hormonal shift is the entire therapeutic basis for the drug's efficacy in hair loss and BPH.

NAD+ participates in androgen biology through a more indirect route. Sirtuins, the NAD+-dependent deacetylases (particularly SIRT1), modulate androgen receptor (AR) transcriptional activity in preclinical models [7]. SIRT1 deacetylates the androgen receptor, which in some cellular contexts reduces AR-driven gene expression. Raising intracellular NAD+ via NMN supplementation could theoretically enhance SIRT1 activity.

Does this create a clinically meaningful interaction? The available evidence suggests it does not, for several reasons. First, the sirtuin-AR interaction has been characterized primarily in prostate cancer cell lines and rodent models, not in the context of hair follicle biology or BPH [7]. Second, the magnitude of NAD+ elevation achieved with oral NMN dosing (typically 250 to 500 mg/day in human trials) produces a modest, systemic increase in NAD+ levels, not the kind of targeted, high-concentration exposure used in cell-culture experiments. Third, finasteride's DHT-lowering effect is upstream of androgen receptor activation. Even if NMN slightly modulated AR sensitivity, the substrate (DHT) would still be reduced by 70%.

The net effect: these two pharmacodynamic pathways are unlikely to produce a clinically relevant interaction at standard doses.

What the Drug Interaction Databases Say

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not list a documented interaction between NMN, NR, or nicotinamide and finasteride. The FDA prescribing information for finasteride notes that "no drug interactions of clinical importance have been identified" and specifically states the drug has been co-administered with other medications without evidence of significant interactions [1].

NMN and NR, as dietary supplements, are not subject to the same FDA labeling requirements as prescription drugs. Neither has an FDA-approved drug label with a formal drug interactions section. The closest pharmacological relative with extensive interaction data is nicotinamide (niacinamide), a downstream metabolite of both NMN and NR. Nicotinamide at therapeutic doses (up to 3 g/day for dermatologic indications) has no documented interaction with 5-alpha reductase inhibitors [8].

One caveat: the absence of a listed interaction does not prove safety with the same rigor as a completed Phase I drug-drug interaction trial. No such trial has been conducted for NMN or NR with finasteride.

Liver Function and Hepatic Load

Both finasteride and high-dose NAD+ precursors undergo hepatic processing, raising a practical question about cumulative liver burden.

Finasteride is generally well-tolerated hepatically. Post-marketing reports of liver enzyme elevation exist but are rare. The FDA label does not include hepatotoxicity as a boxed or bolded warning [1]. In the Prostate Cancer Prevention Trial (PCPT, N=18,882), finasteride 5 mg daily for 7 years did not produce a statistically significant increase in hepatic adverse events compared to placebo [9].

NMN at doses up to 1,250 mg/day for 4 weeks showed no clinically significant liver enzyme elevations in the Fukamizu et al. (2022) dose-escalation study [10]. NR at 1,000 mg/day for 6 weeks similarly produced no hepatotoxicity signals in the Martens et al. trial [3].

For patients already taking finasteride, adding NMN or NR at commonly marketed doses (250 to 500 mg/day for NMN; 300 to 1,000 mg/day for NR) is unlikely to produce additive hepatic stress. Checking a baseline hepatic panel (ALT, AST, ALP) before starting the combination and repeating it at 8 to 12 weeks is reasonable but not mandatory.

Monitoring Recommendations for Co-Administration

No specialized monitoring protocol exists for this combination. Standard care for each agent individually provides adequate oversight.

For finasteride, the 2023 American Urological Association (AUA) guidelines recommend a baseline PSA before starting 5-alpha reductase inhibitors in men being screened for prostate cancer, with the understanding that finasteride approximately halves PSA values [11]. Men using finasteride 1 mg for hair loss should be aware of this effect if they undergo PSA testing.

For NMN/NR, no consensus monitoring guidelines exist. Periodic assessment of fasting glucose is reasonable given the metabolic effects observed in early trials. Some clinicians also check homocysteine levels, since NAD+ metabolism intersects with one-carbon metabolism, though clinical data supporting this practice remain limited.

When the two agents are used together, no additional labs beyond these individual recommendations are indicated. The combination does not warrant therapeutic drug monitoring, dose reduction, or altered timing of administration.

Timing and Practical Dosing Guidance

Finasteride is typically taken once daily without regard to meals [1]. NMN and NR are most commonly taken in the morning, also without strict food requirements, though some formulations recommend administration with food to reduce GI discomfort.

No pharmacokinetic rationale supports separating the doses by a specific time interval. Patients may take both agents simultaneously or at different times based on personal preference. The lack of CYP overlap, transporter competition, or pH-dependent absorption interference means co-ingestion is not expected to alter the bioavailability of either compound.

Special Populations

Certain patient groups warrant additional consideration.

Men over 65. Finasteride's half-life extends with age, and NAD+ levels decline more steeply in older adults. The theoretical benefit of NMN/NR supplementation may be greater in this group, and the interaction risk does not increase. Renal dose adjustment is not required for either agent in mild to moderate renal impairment [1].

Men with hepatic impairment. Finasteride has not been studied in patients with hepatic insufficiency, and the FDA label advises caution [1]. NMN/NR data in liver disease are absent. Co-administering both agents in patients with known liver disease should be approached conservatively with hepatic monitoring every 4 to 6 weeks.

Men taking CYP3A4 inhibitors concurrently. If a patient already uses a strong CYP3A4 inhibitor (ketoconazole, itraconazole, ritonavir), finasteride plasma levels may rise. Adding NMN/NR does not compound this risk, but the overall medication burden deserves review.

What We Do Not Yet Know

Several gaps remain in the evidence base. No randomized controlled trial has evaluated the combination of NMN (or NR) with finasteride as a co-primary intervention. The pharmacodynamic interaction between sirtuin activation and androgen receptor modulation has not been studied in human prostate or scalp tissue at physiologically relevant NAD+ concentrations. Long-term safety data for NMN supplementation beyond 12 weeks are sparse, with the longest published trial (Yi et al., 2023, N=80) extending to 60 days at 600 or 1,200 mg/day [12].

Until dedicated interaction studies are completed, the evidence supports a low-risk classification. Physicians should document NMN/NR use in the patient's supplement list and reassess at routine follow-up visits. The 2024 Endocrine Society position statement on NAD+ precursors noted that "clinicians should inquire about NAD+ booster use given the rapid consumer adoption of these supplements" [13].

Patients taking finasteride 1 mg for hair loss or 5 mg for BPH can co-administer NMN (250 to 500 mg/day) or NR (300 to 1,000 mg/day) without a known pharmacokinetic or pharmacodynamic contraindication; a baseline hepatic panel and routine PSA monitoring (if clinically indicated) represent sufficient oversight for this combination.